Savara (NASDAQ:SVRA) Shares Gap Up – Here’s Why

Savara Inc. (NASDAQ:SVRA – Get Free Report) shares gapped up prior to trading on Wednesday. The stock had previously closed at $4.48, but opened at $4.65. Savara shares last traded at $4.8220, with a volume of 927,384 shares trading hands.

Analysts Set New Price Targets

Several brokerages have commented on SVRA. Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a research note on Sunday, October 4th. Royal Bank Of Canada set a $10.00 price objective on shares of Savara in a research report on Wednesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a report on Thursday, October 15th. Citigroup reaffirmed a “market outperform” rating on shares of Savara in a research report on Wednesday, October 7th. Finally, HC Wainwright initiated coverage on shares of Savara in a research note on Thursday, November 12th. They set a “buy” rating and a $10.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.29.

Read Our Latest Analysis on SVRA

Savara Trading Up 6.4%

The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -7.83 and a beta of 0.32. The company has a debt-to-equity ratio of 0.28, a quick ratio of 8.55 and a current ratio of 8.55. The business has a 50-day moving average of $4.90 and a 200-day moving average of $5.33.

Savara (NASDAQ:SVRA – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01. As a group, research analysts forecast that Savara Inc. will post -0.68 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Savara in the second quarter valued at about $76,966,000. Nantahala Capital Management LLC purchased a new stake in Savara during the second quarter worth about $42,977,150. Spruce Street Capital LP purchased a new stake in Savara during the second quarter worth about $21,267,868. Nan Fung Trinity HK Ltd. grew its position in Savara by 1,088.3% during the third quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company’s stock worth $9,507,000 after buying an additional 1,687,310 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new position in Savara during the second quarter worth about $8,645,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

(Get Free Report)

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

Featured Articles

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.